The effect of clenbuterol and recombinant erythropoietin on tumor growth and the anemia caused by the Walker 256 carcinosarcoma.
In patients with advanced cancer, anemia is a common complication indicative of a poor prognosis. Attempts to alleviate this have met with mixed success and interventions including erythropoietin often fail to elicit an appropriate response. We have used rats implanted with the Walker 256 carcinosarcoma as a model of non-responsive anemia. This study demonstrates that the provision of recombinant erythropoietin in the presence of clenbuterol, a beta2 agonist, attenuates both the cancer induced anemia and the growth of the tumor in this model. We hypothesize that this treatment relieves the tumor induced inhibition of hematopoiesis, which allows for not only an increase in hematocrit but an increased immunosurveillance resulting in tumor suppression.
Gagic
K
K
Dept. of Physiology, LSU School of Medicine, New Orleans, LA. 70112, USA.
Campagnaro
E
E
LaBorde
C J
CJ
Edavettal
M
M
Levine
E A
EA
Potter
B J
BJ
Racey Burns
L A
LA
Burns
A H
AH
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000818:Animals; D002279:Carcinoma 256, Walker / Q000188:drug therapy* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D002976:Clenbuterol / Q000494:pharmacology* / Q000627:therapeutic use; D004921:Erythropoietin / Q000494:pharmacology* / Q000627:therapeutic use; D006400:Hematocrit; D010431:Pentoxifylline / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins
D000318:Adrenergic beta-Agonists; D011994:Recombinant Proteins; D004921:Erythropoietin; D010431:Pentoxifylline; D002976:Clenbuterol